|
|
Line 532: |
Line 532: |
| ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | | ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== |
| *This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | | *This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. |
| | |
| | ===2021: [https://pubmed.ncbi.nlm.nih.gov/33894796/ Switching away from Cigarette Smoking with JUUL: Populations of Special Interest]=== |
| | *Substantial rates of complete switching were consistently achieved across all medico-socio-demographic subgroups 12 months following the purchase of the JSK. The potential benefits of switching with JUUL on smokers are likely to be experienced by a wide range of adult smokers. |
|
| |
|
| ===2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876707/ E-Cigarettes and Smoking Cessation in Smokers With Chronic Conditions]=== | | ===2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876707/ E-Cigarettes and Smoking Cessation in Smokers With Chronic Conditions]=== |